{"pre_text": ["table of contents intangibles 2014goodwill and other in december 2010 , the fasb issued asu 2010-28 , intangibles 2014goodwill and other ( topic 350 ) .", "asu 2010-28 modifies step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts .", "for those reporting units , an entity is required to perform step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists .", "in determining whether it is more likely than not that a goodwill impairment exists , an entity should consider whether there are any adverse qualitative factors indicating that an impairment may exist .", "asu 2010-28 is effective for the company in fiscal 2012 .", "the adoption of asu 2010-28 is not expected to have a material impact on the company 2019s consolidated financial statements .", "in september 2011 , the fasb issued asu no .", "2011-08 , intangibles 2014goodwill and other ( topic 350 ) : testing goodwill for impairment .", "asu 2011-08 allows entities to first assess qualitatively whether it is necessary to perform the two-step goodwill impairment test .", "if an entity believes , as a result of its qualitative assessment , that it is more likely than not that the fair value of a reporting unit is less than its carrying amount , the quantitative two-step impairment test is required ; otherwise , no further testing is required .", "asu 2011-08 is effective for the company beginning in fiscal 2013 , although early adoption is permitted .", "the company does not believe that asu 2011-08 will have a material impact on its consolidated financial statements .", "3 .", "business combinations fiscal 2012 acquisition : gen-probe , inc .", "on august 1 , 2012 , the company completed the acquisition of gen-probe and acquired all of the outstanding shares of gen-probe .", "pursuant to the merger agreement , each share of common stock outstanding immediately prior to the effective time of the acquisition was cancelled and converted into the right to receive $ 82.75 in cash .", "in addition , all outstanding restricted shares , restricted stock units , performance shares , and those stock options granted prior to february 8 , 2012 were cancelled and converted into the right to receive $ 82.75 per share in cash less the applicable exercise price , as applicable .", "stock options granted after february 8 , 2012 were converted into stock options to acquire shares of hologic common stock determined by a conversion formula defined in the merger agreement .", "the company paid the gen-probe shareholders $ 3.8 billion and $ 169.0 million to equity award holders .", "the company funded the acquisition using available cash and financing consisting of senior secured credit facilities and senior notes ( see note 5 for further discussion ) resulting in aggregate proceeds of $ 3.48 billion , excluding financing fees to the underwriters .", "the company incurred approximately $ 34.3 million of direct transaction costs recorded within general and administrative expenses .", "gen-probe , headquartered in san diego , california , is a leader in molecular diagnostics products and services that are used primarily to diagnose human diseases , screen donated human blood , and test transplant compatibility .", "the company expects this acquisition to enhance its molecular diagnostics franchise and to complement its existing portfolio of diagnostics products .", "gen-probe 2019s results of operations are reported within the company 2019s diagnostics reportable segment from the date of acquisition .", "the purchase price consideration was as follows: ."], "post_text": ["the fair value of stock options exchanged recorded as purchase price represents the fair value of the gen-probe options converted into the company 2019s stock options attributable to pre-combination services pursuant to asc 805 , business combinations .", "the remainder of the fair value of these options of $ 23.2 million will be recognized as stock-based compensation expense over the remaining vesting period , which is approximately 3.5 years .", "the company estimated the fair value of the stock options using a binomial valuation model with the following weighted average assumptions : risk free rate of 0.41% ( 0.41 % ) , expected volatility of 39.9% ( 39.9 % ) , expected life of 3.6 years and dividend of 0.0% ( 0.0 % ) .", "the weighted average fair value of stock options granted is $ 7.07 per share .", "source : hologic inc , 10-k , november 28 , 2012 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely .", "the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law .", "past financial performance is no guarantee of future results. ."], "table": [["cash paid", "$ 3967866"], ["deferred payment", "1655"], ["fair value of stock options exchanged", "2655"], ["total purchase price", "$ 3972176"]], "table_ori": [["Cash paid", "$3,967,866"], ["Deferred payment", "1,655"], ["Fair value of stock options exchanged", "2,655"], ["Total purchase price", "$3,972,176"]]}

Question: what is the expected yearly stock-based compensation expense over the remaining vesting period , ( in millions ) ?
Evidence:
text_26: the remainder of the fair value of these options of $ 23.2 million will be recognized as stock-based compensation expense over the remaining vesting period , which is approximately 3.5 years .
Program: divide(23.2, 3.5)
Answer:
str_answer: 6.6
exe_answer: 6.62857